Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an MIR
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • American Society of Hematology (ASH) Annual Meeting and Exposition

67th American Society of Hematology (ASH) Annual Meeting and Exposition

December 06 - 09, 2025

  1. All
  2. AL
  3. HSCT-TMA
  4. PNH
  5. Others

HTML

The ALACRITY study: a phase 1b/2 study of AZD0120 in participants with relapsed or refractory light chain amyloidosis

HTML

Outcomes in pediatric patients with HSCT-TMA treated with ravulizumab

HTML

Organ dysfunction in pediatric patients with HSCT-TMA treated with ravulizumab

HTML

Danicopan add-on therapy demonstrates positive efficacy and safety outcomes in advanced age adults with paroxysmal nocturnal hemoglobinuria and clinically significant extravascular hemolysis: a sub-analysis of the phase 3 ALPHA trial

HTML

Ravulizumab demonstrates real-world effectiveness in patients with paroxysmal nocturnal hemoglobinuria: A US chart review study

HTML

Real-world analysis of ravulizumab safety and effectiveness in advanced age patients with paroxysmal nocturnal hemoglobinuria: insights from the international PNH registry

HTML

Real-world application of AI in expediting Paroxysmal Nocturnal Hemoglobinuria diagnosis

HTML

Successful retreatment of PNH with switch to ravulizumab and add-on danicopan after experiencing breakthrough hemolysis on pegcetacoplan: a case report

HTML

Safety of ravulizumab use in pregnancy: insights from a global pharmacovigilance analysis

HTML

The ALACRITY study: a phase 1b/2 study of AZD0120 in participants with relapsed or refractory light chain amyloidosis

HTML

Outcomes in pediatric patients with HSCT-TMA treated with ravulizumab

HTML

Organ dysfunction in pediatric patients with HSCT-TMA treated with ravulizumab

HTML

Danicopan add-on therapy demonstrates positive efficacy and safety outcomes in advanced age adults with paroxysmal nocturnal hemoglobinuria and clinically significant extravascular hemolysis: a sub-analysis of the phase 3 ALPHA trial

HTML

Ravulizumab demonstrates real-world effectiveness in patients with paroxysmal nocturnal hemoglobinuria: A US chart review study

HTML

Real-world analysis of ravulizumab safety and effectiveness in advanced age patients with paroxysmal nocturnal hemoglobinuria: insights from the international PNH registry

HTML

Real-world application of AI in expediting Paroxysmal Nocturnal Hemoglobinuria diagnosis

HTML

Successful retreatment of PNH with switch to ravulizumab and add-on danicopan after experiencing breakthrough hemolysis on pegcetacoplan: a case report

HTML

Safety of ravulizumab use in pregnancy: insights from a global pharmacovigilance analysis

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 3/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data 
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States